

UPADACITINIB prolonged-release tablets (RINVOQ[®]▼) for treating atopic dermatitis

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of UPADACITINIB prolonged-release tablets (RINVOQ[®]▼) for treating atopic dermatitis

GREY

Upadacitinib has been granted a license extension and is indicated for the treatment of moderate to severe atopic dermatitis in adult patients and adolescents 12 years and over who are candidates for systemic therapy^[1].

This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, clinicians should continue to follow national guidance, local pathways and local formulary choices for the treatment of atopic dermatitis including:

- > [NICE CKS Eczema – Atopic](#) (Last revised July 2021)
- > Pan Mersey Formulary: [Chapter 13 Skin – Drugs affecting the immune response](#)

References

1. AbbVie Ltd. Summary of Product Characteristics; [RINVOQ[®] 15mg prolonged release tablets](#), 25 August 2021. Accessed online 23 September 2021.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.